Names rising to the top of the screen
The strongest names stay in view, with the valuation context behind the ranking.
| # | Ticker | Company | AI Score | Price | Change | Market Cap | P/E |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech, Inc. | 98 | $313.66 | +0.69% | $9.2B | 37.67 |
| 2 | INCY | Incyte Corporation | 98 | $113.31 | -2.07% | $23.0B | 14.23 |
| 3 | AUPH | Aurinia Pharmaceuticals Inc. | 98 | $17.04 | +1.07% | $2.2B | 7.14 |
| 4 | UTHR | United Therapeutics Corporation | 98 | $592.84 | +0.91% | $25.2B | 19.43 |
| 5 | EXEL | Exelixis, Inc. | 98 | $65.11 | +0.90% | $16.2B | 19.61 |
| 6 | NRIX | Nurix Therapeutics, Inc. | 98 | $25.55 | +0.83% | $2.8B | 10.10 |
| 7 | ARGX | argenx SE | 97 | $869.33 | -0.50% | $54.7B | 32.05 |
| 8 | HRMY | Harmony Biosciences Holdings, Inc. | 97 | $36.83 | +1.94% | $2.1B | 11.54 |
| 9 | VRTX | Vertex Pharmaceuticals Incorporated | 97 | $517.49 | -1.23% | $131.0B | 30.25 |
| 10 | HALO | Halozyme Therapeutics, Inc. | 97 | $128.01 | +1.89% | $14.4B | 35.69 |
| 11 | ONC | BeOne Medicines Ltd. | 96 | $370.87 | -1.79% | $39.6B | 27.02 |
| 12 | LGND | Ligand Pharmaceuticals Incorporated | 96 | $308.30 | +1.57% | $6.2B | 30.32 |
Sector mix of the listed stocks
Share of the 12 listed stocks by sector (snapshot 2026-10-26).
Healthcare100%
“MoonshotScore rates a US-listed stock 0 to 100 using five sector-relative pillars. Higher means stronger numbers across business quality, safety, valuation, growth and momentum. Eligible common stocks and ADRs only; funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
How is this list selected and ranked?
This screen includes industry matches biotech; market cap ≥ $1B; US common stocks and ADRs with a MoonshotScore. Results are ordered by MoonshotScore, highest first.
Which snapshot does this list use?
The screen uses recorded provider data and the published ranking formula. Snapshot: 2026-10-26. It is an educational comparison, not a recommendation.